Nov 16, 2022 / 01:35PM GMT
Dae Gon Ha - Stifel Financial Corp. - Analyst
Everyone, thanks for joining this next session. My name is Dae Gon Ha, one of the biotech analysts here at Stifel. So for the next half-hour-ish, we're delighted to have Freeline Therapeutics. And with me on stage here, we've got Michael Parini, CEO. So Michael, thank you very much for your time here.
Michael Parini - Freeline Therapeutics Holdings plc - CEO & Director
Thanks for having us.
Dae Gon Ha - Stifel Financial Corp. - Analyst
Let's start off with a brief overview of Freeline Therapeutics. There are plenty of AAV-oriented gene therapy companies. Tell us what the differentiation, the secret sauce, is that you guys bring to the table.
Michael Parini - Freeline Therapeutics Holdings plc - CEO & Director
Yeah. Thanks. Well, first of all, thanks for having us. We're delighted to be here. Freeline's been around for about seven years or so. And really, the key differentiator that founded the company was the work of
Freeline Therapeutics Holdings PLC at Stifel Healthcare Conference Transcript
Nov 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers